Two prior studies evaluated at the protein level impact UGT protein expression in primary tumour samples, and established correlations with clinical outcomes after prostatectomy.16,23 The first study by Belledant et al.16 utilised a specific polyclonal UGT2B28 antibody, and showed that higher expression levels in primary tumours were associated with more aggressive PCa and greater risk of progression. The gene discussed is UGT2B28; the disease is neoplasm.